DarTTP: an Observational, International, Multicentric Study on Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
• patients with a confirmed diagnosis of iTTP (i.e., ADAMTS13 activity \<10% with anti-ADAMTS13 antibodies detected);
• aged ≥ 18 years;
• male and female patients;
• treated with daratumumab for iTTP.
Locations
Other Locations
Italy
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
RECRUITING
Milan
Contact Information
Primary
Juri A Giannotta, M.D.
juri.giannotta@policlinico.mi.it
+390255035273
Time Frame
Start Date: 2025-10-01
Estimated Completion Date: 2026-08
Participants
Target number of participants: 40
Treatments
Adult patients with iTTP
Patients with a confirmed diagnosis of iTTP, aged ≥ 18 years, treated with daratumumab for iTTP
Related Therapeutic Areas
Sponsors
Leads: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico